Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Amgen Sign Development Deal for Idylla CDx Biomarker Tests

NEW YORK (GenomeWeb) – Biocartis announced today that it has signed a companion diagnostic development agreement with Amgen to develop CDx biomarker tests on its Idylla platform for a compound Amgen is developing to treat certain solid tumors.

Financial terms of the agreement were not disclosed.

"Today's announcement is [an] important step in the expansion of our CDx portfolio, which should contribute to short term revenue generation and create a strong pipeline of future Idylla CDx biomarker tests," Ulkrik Cordes, Biocartis' executive vice president of companion diagnostics, said in a statement.

This is Biocartis second recent CDx agreement with Amgen. In December, the companies signed an agreement to seek a premarket approval for Biocartis' Idylla KRAS Mutation Test and Idylla NRAS-BRAF Mutation Test with the US Food and Drug Administration, as companion diagnostic tests for Amgen's Vectibix (panitumumab), a monoclonal anti-epidermal growth factor receptor antibody approved to treat certain metastatic colorectal cancer patients with wild-type RAS. The two Idylla biomarker tests allow for the simultaneous detection of 44 clinically relevant colorectal cancer mutations from formalin-fixed paraffin embedded tumor slices, Biocartis said. Amgen said it would provide financial and operational support to Biocartis for the PMA process.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.